TELA Bio reported an earnings (EPS) surprise of +11.11% and a revenue surprise of -0.62% for the quarter ended December 2025. The double-digit EPS beat alongside an essentially flat revenue print suggests better-than-expected profitability or cost control but limited top-line upside. These mixed results are likely to produce a modest stock move (single-digit percentage) and leave the stock dependent on upcoming guidance or clinical/pipeline updates for clearer direction.
TELA Bio reported an earnings (EPS) surprise of +11.11% and a revenue surprise of -0.62% for the quarter ended December 2025. The double-digit EPS beat alongside an essentially flat revenue print suggests better-than-expected profitability or cost control but limited top-line upside. These mixed results are likely to produce a modest stock move (single-digit percentage) and leave the stock dependent on upcoming guidance or clinical/pipeline updates for clearer direction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.15
Ticker Sentiment
